TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer
Нема приказа
Аутори
Stanković, MarijaNestorović, A. R.
Tomović, A. M.
Petrović-Stanojević, Nataša
Anđelić-Jelić, M. S.
Dopudja-Pantić, V. B.
Nagorni-Obradović, Lj. M.
Mitić-Milikić, M. M.
Radojković, Dragica
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) are a major cause of morbidity and mortality worldwide. In both diseases airways inflammation plays an important role. Functional promoter polymorphism, at the position -308, of tumor necrosis factor (TNF)-alpha represents attractive potential susceptibilty marker for both diseases. In order to investigate the role of this polymorphism in COPD and LC, a case-control study was performed. The patient groups consisted of 97 subjects with COPD and 70 subjects with LC, while the control group encompassed 102 subjects. Results of our study showed significant decrease of heterozygote for TNF-alpha-308*1/*2 gene variant in COPD group in comparison to controls (p=0.043). According to our results heterozygous carriers of TNF-alpha-308*1/*2 polymorphism had a 2.3-fold decreased risk for COPD development (CR=0.44,95%CI=0.20-0.97). In patients with lung cancer we also observed a trend of decreased distribution of TNF-alpha-308*1/*2 h...eterozygotes, but statistical significance was not achieved. To our knowledge, this is the first study implicating decreased frequency of TNF-alpha-308*1/*2 gene variant in patients with COPD and LC. Although these results need to be confirmed on larger cohort, they represent a new and interesting finding, not reported in other populations tested so far.
Кључне речи:
TNF-alpha-308 promoter polymorphism / lung cancer / COPDИзвор:
Neoplasma, 2009, 56, 4, 348-352Издавач:
- Aepress Sro, Bratislava
Финансирање / пројекти:
- Структурални елементи генома у модулацији фенотипа (RS-MESTD-MPN2006-2010-143051)
DOI: 10.4149/neo_2009_04_348
ISSN: 0028-2685
PubMed: 19469656
WoS: 000271991100011
Scopus: 2-s2.0-68149131465
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Stanković, Marija AU - Nestorović, A. R. AU - Tomović, A. M. AU - Petrović-Stanojević, Nataša AU - Anđelić-Jelić, M. S. AU - Dopudja-Pantić, V. B. AU - Nagorni-Obradović, Lj. M. AU - Mitić-Milikić, M. M. AU - Radojković, Dragica PY - 2009 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/385 AB - Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) are a major cause of morbidity and mortality worldwide. In both diseases airways inflammation plays an important role. Functional promoter polymorphism, at the position -308, of tumor necrosis factor (TNF)-alpha represents attractive potential susceptibilty marker for both diseases. In order to investigate the role of this polymorphism in COPD and LC, a case-control study was performed. The patient groups consisted of 97 subjects with COPD and 70 subjects with LC, while the control group encompassed 102 subjects. Results of our study showed significant decrease of heterozygote for TNF-alpha-308*1/*2 gene variant in COPD group in comparison to controls (p=0.043). According to our results heterozygous carriers of TNF-alpha-308*1/*2 polymorphism had a 2.3-fold decreased risk for COPD development (CR=0.44,95%CI=0.20-0.97). In patients with lung cancer we also observed a trend of decreased distribution of TNF-alpha-308*1/*2 heterozygotes, but statistical significance was not achieved. To our knowledge, this is the first study implicating decreased frequency of TNF-alpha-308*1/*2 gene variant in patients with COPD and LC. Although these results need to be confirmed on larger cohort, they represent a new and interesting finding, not reported in other populations tested so far. PB - Aepress Sro, Bratislava T2 - Neoplasma T1 - TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer EP - 352 IS - 4 SP - 348 VL - 56 DO - 10.4149/neo_2009_04_348 ER -
@article{ author = "Stanković, Marija and Nestorović, A. R. and Tomović, A. M. and Petrović-Stanojević, Nataša and Anđelić-Jelić, M. S. and Dopudja-Pantić, V. B. and Nagorni-Obradović, Lj. M. and Mitić-Milikić, M. M. and Radojković, Dragica", year = "2009", abstract = "Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) are a major cause of morbidity and mortality worldwide. In both diseases airways inflammation plays an important role. Functional promoter polymorphism, at the position -308, of tumor necrosis factor (TNF)-alpha represents attractive potential susceptibilty marker for both diseases. In order to investigate the role of this polymorphism in COPD and LC, a case-control study was performed. The patient groups consisted of 97 subjects with COPD and 70 subjects with LC, while the control group encompassed 102 subjects. Results of our study showed significant decrease of heterozygote for TNF-alpha-308*1/*2 gene variant in COPD group in comparison to controls (p=0.043). According to our results heterozygous carriers of TNF-alpha-308*1/*2 polymorphism had a 2.3-fold decreased risk for COPD development (CR=0.44,95%CI=0.20-0.97). In patients with lung cancer we also observed a trend of decreased distribution of TNF-alpha-308*1/*2 heterozygotes, but statistical significance was not achieved. To our knowledge, this is the first study implicating decreased frequency of TNF-alpha-308*1/*2 gene variant in patients with COPD and LC. Although these results need to be confirmed on larger cohort, they represent a new and interesting finding, not reported in other populations tested so far.", publisher = "Aepress Sro, Bratislava", journal = "Neoplasma", title = "TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer", pages = "352-348", number = "4", volume = "56", doi = "10.4149/neo_2009_04_348" }
Stanković, M., Nestorović, A. R., Tomović, A. M., Petrović-Stanojević, N., Anđelić-Jelić, M. S., Dopudja-Pantić, V. B., Nagorni-Obradović, Lj. M., Mitić-Milikić, M. M.,& Radojković, D.. (2009). TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. in Neoplasma Aepress Sro, Bratislava., 56(4), 348-352. https://doi.org/10.4149/neo_2009_04_348
Stanković M, Nestorović AR, Tomović AM, Petrović-Stanojević N, Anđelić-Jelić MS, Dopudja-Pantić VB, Nagorni-Obradović LM, Mitić-Milikić MM, Radojković D. TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. in Neoplasma. 2009;56(4):348-352. doi:10.4149/neo_2009_04_348 .
Stanković, Marija, Nestorović, A. R., Tomović, A. M., Petrović-Stanojević, Nataša, Anđelić-Jelić, M. S., Dopudja-Pantić, V. B., Nagorni-Obradović, Lj. M., Mitić-Milikić, M. M., Radojković, Dragica, "TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer" in Neoplasma, 56, no. 4 (2009):348-352, https://doi.org/10.4149/neo_2009_04_348 . .